Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egetis Therapeutics AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Egetis Therapeutics AB's 5-Year Yield-on-Cost % or its related term are showing as below:
LTS:0ABW's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.695 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Egetis Therapeutics AB (LTS:0ABW) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Egetis Therapeutics AB 5-Year Yield-on-Cost % Related Terms
LTS:0ABW vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Egetis Therapeutics AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egetis Therapeutics AB 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Egetis Therapeutics AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Egetis Therapeutics AB's 5-Year Yield-on-Cost % falls into.
Egetis Therapeutics AB 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Egetis Therapeutics AB (LTS:0ABW) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 29, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Egetis Therapeutics AB and its competitors. According to the industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 150 companies in the Biotechnology industry.
Is Egetis Therapeutics AB's 5-Year Yield-on-Cost % too high?
Egetis Therapeutics AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Egetis Therapeutics AB ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Egetis Therapeutics AB has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egetis Therapeutics AB's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Egetis Therapeutics AB ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Egetis Therapeutics AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Egetis Therapeutics AB and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egetis Therapeutics AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egetis Therapeutics AB stock overvalued right now?
Based on GuruFocus' analysis, Egetis Therapeutics AB (LTS:0ABW) is currently considered Modestly Overvalued. The stock's GF Value™ is kr5.65, compared to a current price of kr6.64 — trading 17.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Egetis Therapeutics AB's overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Egetis Therapeutics AB (LTS:0ABW), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egetis Therapeutics AB (LTS:0ABW) Overvalued in 2026?
Based on GuruFocus' analysis, Egetis Therapeutics AB stock appears to be overvalued.
The current stock price of kr6.64 is trading 17.5% above its estimated GF Value™ of kr5.65.
GuruFocus considers Egetis Therapeutics AB to be Modestly Overvalued.
Key valuation signals for LTS:0ABW:
5-Year Yield-on-Cost %: 0.00
GF Value™: kr5.65 vs. price of kr6.64 (17.5% above fair value)
No single metric tells the full story. See the LTS:0ABW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
68GF Score
Get the complete analysis for LTS:0ABW
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0ABW has been successfully added to your 
